Cointime

Xeno Biosciences

company

About

Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.

  • 1 - 10

Highlights

Total Funding Amount
$7.25M
Funding Rounds
1
Investors
4

Details

Last Funding Type
Series A
Last Funding Money Raised
$7.25M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases.

Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.

It was founded in 2015 and is headquartered in Somerville, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$7.25M
Xeno Biosciences has raised a total of $7.25M in funding over 2 rounds. Their latest funding was raised on Aug 8, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 8, 2021 Series A $7.25M 4 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
4
Xeno Biosciences is funded by 4 investors. Dirigo Angels and Bangor Angels are the most recent investors.
Investor Name Lead Investor Funding Round
Dirigo Angels — Series A
Bangor Angels — Series A
Zhi Gao Holding — Series A
Keiretsu Forum — Series A
Cointime
เนื้อหา
บริษัท